BIOCRYST PHARMACEUTICALS, INC. Restricted Cash and Cash Equivalents
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Restricted Cash and Cash Equivalents of $1.41 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-05
- 2026-06-30: Restricted Cash and Cash Equivalents $1.41M.
- 2025-12-31: Restricted Cash and Cash Equivalents $1.60M.
- 2024-12-31: Restricted Cash and Cash Equivalents $1.61M.
- 2024-09-30: Restricted Cash and Cash Equivalents $2.22M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $1.41M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $1.60M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $1.61M 10-K · filed 2025-02-25 |
| 2024-09-30 | $2.22M 10-Q · filed 2024-11-05 |
| 2023-12-31 | $1.80M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |